Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 101


A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis.

Etheridge SL, Cosgrove ME, Sangkhae V, Corbo LM, Roh ME, Seeliger MA, Chan EL, Hitchcock IS.

Blood. 2014 Feb 13;123(7):1059-68. doi: 10.1182/blood-2012-12-473777. Epub 2013 Dec 31.


Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors.

Marty C, Saint-Martin C, Pecquet C, Grosjean S, Saliba J, Mouton C, Leroy E, Harutyunyan AS, Abgrall JF, Favier R, Toussaint A, Solary E, Kralovics R, Constantinescu SN, Najman A, Vainchenker W, Plo I, Bellanné-Chantelot C.

Blood. 2014 Feb 27;123(9):1372-83. doi: 10.1182/blood-2013-05-504555. Epub 2014 Jan 7.


New advances in the pathogenesis and therapy of essential thrombocythemia.

Levine RL, Heaney M.

Hematology Am Soc Hematol Educ Program. 2008:76-82. doi: 10.1182/asheducation-2008.1.76. Review.


JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.

Kilpivaara O, Levine RL.

Leukemia. 2008 Oct;22(10):1813-7. doi: 10.1038/leu.2008.229. Epub 2008 Aug 28. Review.


Impact of isolated germline JAK2V617I mutation on human hematopoiesis.

Mead AJ, Chowdhury O, Pecquet C, Dusa A, Woll P, Atkinson D, Burns A, Score J, Rugless M, Clifford R, Moule S, Bienz N, Vyas P, Cross N, Gale RE, Henderson S, Constantinescu SN, Schuh A, Jacobsen SE.

Blood. 2013 May 16;121(20):4156-65. doi: 10.1182/blood-2012-05-430926. Epub 2013 Mar 27.


JAK and MPL mutations in myeloid malignancies.

Tefferi A.

Leuk Lymphoma. 2008 Mar;49(3):388-97. doi: 10.1080/10428190801895360. Review.


JAK2 mutations and clinical practice in myeloproliferative neoplasms.

Tefferi A.

Cancer J. 2007 Nov-Dec;13(6):366-71. Review.


[Myeloproliferative diseases caused by JAK2 mutation].

Nagata K, Shimoda K.

Rinsho Byori. 2009 Apr;57(4):357-64. Review. Japanese.


Somatic mutations of calreticulin in myeloproliferative neoplasms.

Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant'Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schönegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R.

N Engl J Med. 2013 Dec 19;369(25):2379-90. doi: 10.1056/NEJMoa1311347. Epub 2013 Dec 10.


JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling.

Schwemmers S, Will B, Waller CF, Abdulkarim K, Johansson P, Andreasson B, Pahl HL.

Exp Hematol. 2007 Nov;35(11):1695-703. Epub 2007 Aug 30.


[Detection of the JAK2 gene mutation in familial myeloproliferative neoplasm and its clinical significance].

Zhang YM, Hao LX, Wei Q, Wei YQ, Huang F, Zhang Y, Yin CX, Feng R.

Zhonghua Xue Ye Xue Za Zhi. 2012 Feb;33(2):103-7. Chinese.


Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.

Hoermann G, Cerny-Reiterer S, Herrmann H, Blatt K, Bilban M, Gisslinger H, Gisslinger B, Müllauer L, Kralovics R, Mannhalter C, Valent P, Mayerhofer M.

FASEB J. 2012 Feb;26(2):894-906. doi: 10.1096/fj.11-193078. Epub 2011 Nov 3.


Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients.

Patriarca A, Pompetti F, Malizia R, Iuliani O, Di Marzio I, Spadano A, Dragani A.

Blood Transfus. 2010 Jan;8(1):21-7. doi: 10.2450/2009.0004-09.


Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.

Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A.

Leukemia. 2008 Jul;22(7):1299-307. doi: 10.1038/leu.2008.113. Epub 2008 May 22. Review.


The spectrum of JAK2-positive myeloproliferative neoplasms.

Kiladjian JJ.

Hematology Am Soc Hematol Educ Program. 2012;2012:561-6. doi: 10.1182/asheducation-2012.1.561. Review.


Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.

Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foà R, Larocca LM.

J Clin Oncol. 2007 Mar 20;25(9):1048-53.


The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms.

Olcaydu D, Rumi E, Harutyunyan A, Passamonti F, Pietra D, Pascutto C, Berg T, Jäger R, Hammond E, Cazzola M, Kralovics R.

Haematologica. 2011 Mar;96(3):367-74. doi: 10.3324/haematol.2010.034488. Epub 2010 Dec 20.


A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

Olcaydu D, Harutyunyan A, Jäger R, Berg T, Gisslinger B, Pabinger I, Gisslinger H, Kralovics R.

Nat Genet. 2009 Apr;41(4):450-4. doi: 10.1038/ng.341. Epub 2009 Mar 15.


Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms.

Anand S, Stedham F, Gudgin E, Campbell P, Beer P, Green AR, Huntly BJ.

Blood. 2011 Aug 11;118(6):1610-21. doi: 10.1182/blood-2011-02-335042. Epub 2011 Jun 8.


Absence of FTL3 mutations in patients with JAK2V617F mutation negative essential thrombocythemia.

Medeiros BC, Zhang T, Lipton JH, Kamel-Reid S.

Am J Hematol. 2007 Apr;82(4):293-4.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk